Actinic keratoses - a systemic review

Cover Page

Abstract


Актиническому кератозу (АК) в основном подвержены пожилые люди со светлой кожей. За последние годы в связи с демографическими изменениями увеличилась распространенность АК. установленным фактором риска, приводящим к возникновению мутаций в антионкогене TP53 и онкогене H-Ras, является хроническое ультрафиолетовое воздействие (работа на открытом воздухе), которое способствует внутриэпидермальной пролиферации атипичных кератиноцитов. термин «поле канцеризации» характеризуется наличием множественного АК в участках, подверженных УФ-облучению. также АК называется преинвазивной плоскоклеточной карциномой или плоскоклеточной карциномой in situ. Риск превращения АК в плоскоклеточную карциному составляет 6-10%. Во избежание инвазивного роста рекомендуется лечение на ранних стадиях. За последние годы были разработаны различные варианты терапевтического лечения. В зависимости от степени выраженности признаков существуют методы терапии, направленные на поврежденные участки и дающие превосходные косметические и клинические результаты.

T. . Strunk

Academic Teaching Hospital

Author for correspondence.
Email: Strunk@klinikum-vest.de

Russian Federation

L. R. Braathen

Dermatology Bern

Email: noemail@neicon.ru

Russian Federation

R. -M. Szeimies

Academic Teaching Hospital

Email: noemail@neicon.ru

Russian Federation

  1. Pinkus H. Keratosis senilis: a biologic concept of its pathogenesis and diagnosis based on the study of normal epidermis and 1730 seborrheic and senile keratoses. Am J Clin Pathol 1958; 29: 193-207.
  2. Memon A.A., Tomenson J.A., Bothwell J. et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
  3. Schaefer I., Augustin M., Spehr C. et al. Prevalence and risk factors of actinic keratoses in Germany - analysis of multisource data. J Eur Acad Dermatol Venereol 2013; 28: 309-13.
  4. Traianou A., Ulrich M., Apalla Z. et al. Risk factors for actinic keratosis in eight European centers: a case-control study. Br J Dermatol 2012; 167(Suppl 2): 36-42.
  5. Hensen P., Müller M.L., Haschemi R. et al. Predisposing factors of actinic keratosis in a NorthWest German population. Eur J Dermatol 2009; 19: 345-54.
  6. Oldenburg M., Kuechmeister B., Ohnemus U. et al. Actinic keratosis among seafarers. Arch Dermatol Res 2013; 305: 787-96.
  7. Schmitt J., Seidler A., Diepgen T.L. et al. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 2011; 164: 291-307.
  8. Ulrich C., Schmook T., Nindl I. et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 2003; 149(Suppl 2): 40-2.
  9. Babilas P., Landthaler M., Szeimies R.M. Actinic keratoses. Hautarzt 2003; 54: 551-62.
  10. Luo J.L., Tong W.M., Yoon J.H. et al. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot e.g. in sun-exposed human skin. Cancer Res 2001; 61: 8158-63.
  11. Tomas D. Apoptosis, UV-radiation, precancer-osis and skin tumor. Acta Med Croatica 2009; 63(Suppl 2): 53-8.
  12. Pierceall W.E., Goldberg L.H., Tainsky M.A. et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4: 196-202.
  13. Ratushny V., Gober M.D., Hick R. et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012; 122: 464-72.
  14. Lacouture M.E., Duvic M., Hauschild A. et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
  15. Zaravinos A., Kanellou P., Spandidos D.A. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol 2009; 162: 325-31.
  16. Weissenborn S.J., Nindl I., Purdie K. et al. Human Papilloma Virus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125: 93-7.
  17. Pfister H. HPV and skin dose. Hautarzt 2008; 59: 26-30.
  18. Nashan D., Meiss F., Muller M. Therapeutic strategies for actinic keratoses-a systematic review. Eur J Dermatol 2013; 23: 14-32.
  19. Branzan A.L., Landthaler M., Szeimies R.M. In vivo confocal scanning laser microscopy in dermatology. Lasers Med Sci 2007; 22: 73-82.
  20. Röwert-Huber J., Patel M.J., Forschner T. et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 (Suppl 3): 8-12.
  21. Cockerell C.J. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis”). J Am Acad Dermatol 2000; 42(1 Pt 2): 11-7.
  22. Cockerell C.J. Pathology and pathobiology of the actinic (solar) keratosis. Br J Dermatol 2003; 149 (Suppl 66):The code 34-6.
  23. Ramos-Ceballos F.I., Ounpraseuth S.T., Horn T.D. Diagnostic concordance among dermatopatholo-gists using a three-tiered keratinocytic intraepithelial neoplasia grading scheme. J Cutan Pathol 2008; 35: 386-91.
  24. Werner R.N., Sammain A., Erdmann R. et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502-18.
  25. Marks R., Foley P., Goodman G. et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
  26. Dodson J.M., DeSpain J., Hewett J.E. et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991; 127: 1029-31.
  27. Fuchs A., Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007; 33: 1099-101.
  28. Braathen L.R., Morton C.A., Basset-Seguin N. et al. Photodynamic therapy for skin field cancer-ization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 1063-6.
  29. Ulrich C., Jürgensen J.S., Degen A. et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl 3): 78-84.
  30. Patel G., Armstrong A.W., Eisen D.B. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: A systematic review and metaanalysis. JAMA Dermatol doi: 10.1001/jamadermatol. 2014.1253. [Epub ahead of print].
  31. Andrews M.D. Cryosurgery for common skin conditions. Am Fam Physician 2004; 69: 2365-72.
  32. Thai K.E., Fergin P., Freeman M. A prospective study of the use of Cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004; 43: 687-92.
  33. Kaufmann R., Spelman L., Weightman W. et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994-9.
  34. Szeimies R.M., Karrer S., Radakovic-Fijan S. et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
  35. Wollina U., Konrad H., Karamfilov T. Treatment of common queue and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 2001; 3: 63-6.
  36. Stockfleth E., Kerl H., Zwingers T. et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101-8.
  37. Hauschild A., Stockfleth E., Popp G. et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-74.
  38. Szeimies R.M., Stockfleth E., Popp G. et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010; 162: 410-4.
  39. Pflugfelder A., Welter A.K., Leiter U. et al. Open label randomized study comparing 3 months vs. 6 Months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 2012; 26: 48-53.
  40. Iraji F., Siadat A.H., Asilian A. et al. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 2008; 7: 167-72.
  41. Alomar A., Bichel J., McRae S. vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
  42. Lebwohl M., Dinehart S., Whiting D. et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
  43. Korman N., Moy R., Ling M. et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallelgroup, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
  44. Swanson N., Abramovits W., Berman B. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebocontrolled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-90.
  45. Hanke C.W., Beer K.R., Stockfleth E. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62: 573-81.
  46. Swanson N., Smith C.C., Kaur M. et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol 2013; 12: 1278-82.
  47. Lebwohl M., Swanson N., Anderson L.L. et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-9.
  48. Lebwohl M., Shumack S., Stein Gold L. et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666-70.
  49. Berman B., Goldenberg G., Hanke C.W. et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol 2014; 13: 154-60.
  50. Berman B., Goldenberg G., Hanke C.W. et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 2014; 13: 741-7.
  51. Jury C.S., Ramraka-Jones V.S., Gudi V. et al. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005; 153: 808-10.
  52. Loven K., Stein L., Furst K. et al. Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000.
  53. Sander C.A., Pfeiffer C., Kligman A.M. et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997; 36(2 Pt 1): 236-8.
  54. Szeimies R.M., Karrer S., Bäcker H. Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen’s disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt 2005; 56: 430-40.
  55. Dirschka T., Radny P., Dominicus R. et al. Longterm (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168: 825-36.
  56. Szeimies R.M., Torezan L., Niwa A. et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-9.
  57. Apalla Z., Sotiriou E., Chovarda E. et al. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-5.
  58. Morton C.A., Szeimies R.M., Sidoroff A. et al. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-44.
  59. Wiegell S.R., Fabricius S., Stender I.M. et al. A randomized, multicentre study of directed daylight exposure times of 1/ vs. 2% H in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083-90.
  60. Szeimies R.M., Basset-Seguin N., Rubel D. et al. Efficacy and safety of methyl aminolaevulinate cream activated by daylight in actinic keratosis: two randomized, investigator-blinded, controlled phase 3 studies in Europe and Australia. Br J Dermatol 2014; 171(Suppl. 4): 76.
  61. Togsverd-Bo K., Haak C.S., Thaysen-Petersen D. et al. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol 2012; 166: 1262-9.
  62. Torezan L., Chaves Y., Niwa A. et al. A pilot split-face study comparing conventional methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin. Dermatol Surg 2013; 39: 1197-201.
  63. Serra-Guillén C., Nagore E., Hueso L. et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66: 131-7.
  64. Ondo A.L., Padilla R.S., Miedler J.D., Cockerell C.J. et al. Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: a case-control study. Dermatol Surg 2012; 38: 1469-76.
  65. Reifenberger J., Schön M.P. Cutaneous epithelial tumor. Molecular biology and pathogenesis-based therapy. Hautarzt 2003; 54: 1164-70.

Views

Abstract - 109

PDF (Russian) - 112

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies